ArticleAIDS and behavior2026
Perspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Singapore has yet to conduct an HIV cure trial, and analytical treatment interruption (ATI) studies may face community scepticism. This study explores the perspectives of people living with HIV and healthcare providers in Singapore on participating in functional cure research involving ATI. Participants were recruited from four HIV care facilities through study advertisements. Healthcare providers were recruited via email. A self-administered survey gathered demographic data, views on ATI and HIV cure, acceptability of ATI, and tolerance for CD4 and viral load changes during ATI. Descriptive, univariate, and multivariable logistic regression analyses were used to identify barriers and motivators to trial participation. Among 200 people living with HIV, 116 (58%) expressed willingness to participate in a cure trial; 84 (42%) did not. Most (94.5%, 189/200) had never joined an HIV clinical study. No significant differences in age, gender, sexuality, or HIV duration were observed between the groups. Factors positively associated with willingness to participate included tertiary education (aOR 2.71, 95% CI 1.13-6.81), altruistic motivations (aOR 1.98, 95% CI 1.52-2.66), and financial compensation (aOR 3.55, 95% CI 1.36-9.88). Lower tolerance for viral load increases or CD4 declines was linked to reduced willingness (aOR 0.77, 95% CI 0.67-0.88). Monitoring frequency, self-testing, and home visits had no significant effect. Healthcare providers were more likely to recommend participation in cure trials if they demonstrated high tolerance for HIV viral load increases (p = 0.044), showed stronger interest in cure research (p = 0.009) and expressed greater acceptance of a functional HIV cure (p = 0.014). Willingness to participate in ATI cure trials is higher among individuals with more education, altruistic intent, and less concern about virologic or immunologic changes. Financial compensation is a strong motivating factor but should not play undue inducement in influencing decision to participate in an ATI cure trial. Community engagement and education are crucial to building support for future HIV cure research.
Indexed as
Identifiers
41843255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.